Roche NimbleGen and BioDiscovery Form Strategic Alliance to Enhance CGH Microarrays, Software and Services

Roche NimbleGen Inc., a company of Roche Applied Science, announced today that it has formed a strategic alliance with BioDiscovery, Inc. to offer complete solutions to comparative genomic hybridization (CGH) microarray customers. The new high-density 2.1 million probe (HD2) arrays of Roche NimbleGen combined with industry-leading proprietary software, Nexus Copy Number, of BioDiscovery bring unprecedented power and ease in whole-genome CGH analysis. As part of this alliance Roche NimbleGen and BioDiscovery will co-market and co-promote their products and services to scientists worldwide. The companies also plan to present data generated from NimbleGen CGH arrays using Nexus software of BioDiscovery to the research community through a series of seminars.

Source: Roche Nimblegen